An overview of seventeen years of experience with dothiepin in the treatment of depression in Europe

B. J. Goldstein, J. L. Claghorn

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The European clinical experience with dothiepin since 1962 indicates that it is efficacious in the treatment of depression (neurotic, psychotic, and with concomitant anxiety) in dose of 75-200 mg/day. The side effects profile is similar to the tricyclic antidepressant drugs with significantly less anticholinergic side effects and cardiotoxicity than amitriptyline. The results of the current ongoing clinical trials in the United States with several hundred patients will more precisely define the efficacy, dosage and side effect profile of dothiepin.

Original languageEnglish (US)
Pages (from-to)64-70
Number of pages7
JournalJournal of Clinical Psychiatry
Volume41
Issue number12 II
StatePublished - Dec 1 1980

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'An overview of seventeen years of experience with dothiepin in the treatment of depression in Europe'. Together they form a unique fingerprint.

  • Cite this